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Abstract 
The onset of type 1 diabetes coincides with the final phase of β-cell destruction. In some cases, this period is 
characterized by the presence of a functional reserve of β-cells, favouring an adequate metabolic control (honeymoon 
phase). Therefore, the extension of this situation could have evident benefits in subsequent diabetes management. We 
aimed to study the influence of regular physical activity before and after the onset of the disease. We did an 
observational study of 2 groups of type 1 diabetic patients from onset to a 2-year period. One group (n = 8) exercised 
regularly (5 or more hours/week) before onset and continued doing so with the same regularity. The second group (n 
= 11) either did not perform physical activity or did so sporadically. Circulating glycated haemoglobin (HbA1c), C-
peptide, protein carbonyls and basal cytokine levels were determined at the beginning and at the end of the 1(st) and 
2(nd) year. The more active group debuted with and maintained significantly lower HbA(1c) levels and insulin 
requirements compared to the more sedentary group. C-peptide levels were only significantly higher in the active 
group at the moment of onset compared to the sedentary group. In addition, determination of basal circulating 
cytokines revealed a large variability between individuals but no significant differences when comparing the groups. 
Altogether, the obtained results seem to indicate that physical activity allows a better control at the moment of onset 
regarding glycaemic control, residual endocrine pancreatic mass and subsequent insulin requirements. 
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Introduction 
The clinical symptoms of type 1 diabetes coincide with the final phase of β-cell destruction. This stage 
presents islet inflammation or insulitis, enhanced HLA (human leukocyte antigens) expression, presence 
of β-cell autoantibodies (antiGAD, antiIA-2, antiICA or anti-insulin among others) and β-cell 
dysfunction. Mononuclear cells infiltrate into the islet tissue, including CD4
+
 and CD8
+
 T-lymphocytes, 
macrophages and components of the complement system [1]. The high expression of HLA molecules and 
antigen transporter proteins indicates an enhanced antigen-presenting activity in the islet tissue, where the 
β-cell plays an instrumental role. Once the autoimmune process is activated by auto-reactive T-cells, the 
stimulation continues due to the presence of auto-antigens, leading to the expansion of effector cells and 
increasing the attack against β-cells [2]. 
 
Activated T-lymphocytes exist in circulation and in islet infiltrate. Under normal conditions, they are 
generally controlled by auto-tolerance mechanisms, however under diabetic conditions such control fails, 
leading to a cascade of inflammatory processes that culminate in insulitis. The pathogenic immune 
response is mediated by Th1 lymphocytes and the protection by the Th2 subset. These populations are 
characterized by the production of different types of cytokines. Th1 subset secretes pro-inflammatory 
cytokines such as TNF-α, IFN-γ, IL-1β and IL-12, while Th2 lymphocytes produce anti-inflammatory IL-
4, IL-6 and IL-10 cytokines [3]. 
 
As previously mentioned, the destruction of pancreatic β-cells marks the initiation of the disease. 
However, in many cases a β-cell residual function exists at the moment of onset, allowing a good control 
of hyperglycaemia during a variable period of time. This transient phase is known as the honeymoon 
period. In this sense, several cohort studies and a retrospective analysis of the DCCT (Diabetes Control 
and Complication Trial) demonstrated the benefits of preserving over years a residual β-cell function, 
monitored by C-peptide detection in circulation. These benefits are circumscribed to improved glycated 
haemoglobin (HbA1C) levels and reduction of severe hypoglycaemia crisis. Initial studies seem to indicate 
that this metabolic stability correlates with a preserved β-cell function [4]. This is of particular interest in 
certain moments of the patient’s life, such as during adolescence, where the metabolic control of the 
disease is complicated due to the acquisition of new responsibilities and the lack of interest for certain 
topics, such as disease management. In addition, the DCCT indicates a low frequency to develop long-
term complications, a reduced risk of ketoacidosis and better response to immunotherapy [4]. 
 
Therefore, the question is which strategies could help to debut with a significant residual β-cell mass 
at the moment of onset. Several pharmacological agents such as cyclosporine, azathioprine and 
prednisone were initially used to this end, but quickly discarded due to their secondary effects [5]. More 
recently, phase III trials using monoclonal antibodies against CD3 failed to retard the destruction of β-
cells, although a single-dose regime yielded interesting results in young patients [6]. Other 
pharmacological compounds are still in the experimental phase. These include rituximab that acts by 
suppressing anti-insulin antibodies with no effect in other islet auto-antibodies [7]. The same rational can 
be applied to anti-GAD antibodies, which act exclusively upon the GAD-expressing specific populations 
of β-cells [6]. Other experimental therapies include antibodies against CTLA4/CD152 which is a 
stimulatory molecule similar to CD28 that is expressed in T-helper cells [7]. Finally etanercept, a 
blocking agent of the TNF-α receptor, may affect other cellular responses in other organs where this 
cytokine is playing a signalling role [8]. Therefore, more research is necessary concerning the use of 
pharmacological agents. 
 
On the other hand, several studies underline the metabolic and psychological advantages of physical 
exercise in the management of type 1 diabetes once the disease has been established and the onset period 
passed [9] [10]. However, there are no studies focused on the influence of physical activity at the moment 
of onset. With this objective, we have conducted an observational study in a group of patients at the 
moment of onset and during the subsequent 2 years. The group that regularly performed physical activity 
before, during and after the onset of diabetes presented low levels of HbA1c as well as less exogenous 
insulin requirement. In addition, the more active group presented significant high circulating C-peptide 
levels only at the moment of onset. Values of protein carbonyl and circulating cytokines were not 
significantly different comparing both groups. 
Materials and Methods 
Subjects and study design 
The key element of the pilot study design took in account that in the moment of onset, patients were 
asked about their habits on physical activity, being included in either Group A (for active) or Group S (for 
sedentary) ([Fig. 1]). 19 subjects from 26 with recent onset of type 1 diabetes completed the 2 years study 
in the Endocrinology Service of the University Hospital Complex of A Coruña (Spain). The pilot study 
was registered in ClinicalTrials.gov (ID#: NCT 01789190) and approved by the Autonomic Ethics 
Committee and met both local requirements as well as those stated in the Helsinki Declaration for 
research on human beings. The inclusion criteria for group distribution took in account the principles of 
the American College of Sports Medicine, considering as active physical activity to practice a moderate-
vigorous exercise during 1 h, 5 days or more/week. In this context, a sedentary or less active person 
should be a person that practices any or less than 5 h weekly [11]. Since this is an observational pilot 
study, we could not prescribe exercise nor intervene in the exercise routine of the volunteers. The 
information concerning the physical activity programmes was provided by each participant and recorded 
in the clinical story. Briefly, information concerning the type of exercise, training periods (hours/day), 
competition time (days/week), resting (days/week) and incidences (lesions, holidays, stages, trips, etc.) 
were recorded. Although we could not directly measure the intensity of exercise, nevertheless, each 
participant indicated its own perception about the intensity of work and this information was also 
included in the story. Therefore, group A (n=8) included patients that used to perform regular physical 
activity before onset and continued practicing afterwards with the same regularity. Group S (n=11) 
included patients that did not perform any physical activity at the moment of onset, continuing with the 
same habits during the subsequent observational period. 4 individuals of this group started to practice 
moderate exercise for a maximum of 3 days a week during sporadic moments of the observational period 
(less than 1 h each session). All individuals were informed at the beginning, in the presence of tutors in 
the case of minors, about the objective and justification of the study and signed a written consent. The 
informed consent included the following items in a total of 7 pages: Introduction (indicating the main idea 
of the study), Description (study design), Risks (concerning routine blood sample collection), 
Confidentiality (samples were codified to preserve anonymity), Benefits (there is no economic 
compensation to participate), Results (they will be submitted to scientific publication), Voluntary 
participation (participants can leave the study at any moment), Additional information (Spanish laws that 
regulate the study), Remaining samples (they will be custodied in the Hospital’s Bank) and Letter of 
Consent (including data of each individual and signatures). 
  
 
 
 
Fig. 1 Flow diagram for study design. 
  
The mean age of group A was 21.9±4.2 years and included 8 individuals, 5 men and 3 women 
diagnosed at the moment of onset by hyperglycaemia (n=2), hyperglycaemia+ketoacidosis (n=4) or 
ketoacidosis (n=2). The mean age of group S was 23.3±2.2 years and included 11 individuals, 7 men and 
4 women diagnosed at the moment of onset by hyperglycaemia (n=1), hyperglycaemia+ketoacidosis 
(n=3) or ketoacidosis (n=7). A clinical story and physical exploration was also performed in the first 
consultation. Fasting blood samples were taken from the antecubital vein to determine HbA1c, C-peptide, 
antiGAD, cytokines and protein carbonyls. Patients and tutors entered the hospital educational program in 
order to learn about diet management, glycaemia monitoring and insulin injections. 
 
Consultations were initially performed on a weekly basis for the first month, then once a month for 
the remaining period. In each consultation, patients were asked about diet accomplishment, glycaemia 
monitoring, insulin injections and exercise performance. All individuals from group A declared to 
practice regularly intervallic routines, playing team sports (basketball for n=1 and soccer for n=6). Only 
one individual declared to perform aerobic exercise (long distance running and swimming). At the end of 
the first year a second blood sample was extracted in the same conditions from each individual to 
determine the same parameters. Exercise routine accomplishment and follow-up of diet and insulin 
injections was followed monthly during one more year. At the end of this period, the pilot study was 
considered finished and the last blood extraction was performed in order to measure the same parameters. 
Other subjects were excluded because they were not capable to provide data required for study follow-up. 
Circulating HbA1c, C-peptide and protein carbonyl determinations 
HbA1c was determined by immunoanalysis. C-peptide was determined by radioimmunoassay using 
the Coat-a-Count kit (Diagnosis Products Corporation, LA). Protein carbonyl derivatives were calculated 
by adapting the method developed by Levine (1994) [12]. 
Circulating cytokine determinations 
Cytokines were measured in plasma by Flow Cytometry (FACSCalibur, BD Bioscience) through the 
Flowcytomix
TM
 Multiplex Test (eBioscience) (n=3). The following cytokines were analysed for each 
patient: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17a, IL-22, TNF-α and INF-γ. 
Statistical analysis 
Statistical analysis was performed using the SPSS-20 software for Windows. Normality testing was 
performed according to the Kolmogorov-Smirnov test (K-S test). Results in [Table 1] were expressed as 
the mean±sem and the values with a p<0.05 were considered statistically significant. The effect of 
physical activity on the changes induced in the different circulating parameters (HbA1c, C-peptide, protein 
carbonyls and cytokines) and injected insulin at each particular time was tested by Student t-test for 
independent samples. The evolution of the different cytokines into each particular group of individuals 
throughout time was analysed by Student t-test for paired samples. Although there is a limitation in the 
sample size (n=8 for group A and n=11 for group S), we have performed additional analyses such as a 
general lineal model (GLM) of repeated measures considering time as an intragroup factor and physical 
activity as an intergroup factor, and a GLM of repeated measures considering only the intragroup factor 
(time) and no intergroup factor. Correlation between different parameters was performed according to 
Pearson’s correlation coefficient. We considered arbitrarily a low correlation at r=± 0–0.30, moderate at 
r=± 0.31–0.60 and good at r=± 0.61–1. 
 
  
Table 1 Circulating values for HbA1c, insulin requirements, C-peptide, IDAA1C, protein carbonyls and BMI in the 
active (A) (n=8) and sedentary group (S) (n=11). 
 
Group A Group S 
   
Time 0    
HbA1c (%) 9.57±3.47* 12.68±2.83 
injected insulin (IU/kg of weight) 0.48±0.38 0.72±0.27 
total insulin injected (IU) 31.71±9.74 44.67±5.25 
C-peptide (pmol/L) 1.09±0.76* 0.37±0.13 
IDAA1C 11.50±4.95 15.02±3.03 
protein carbonyls (μmol/L) 76.19±40.62 75.64±12.43 
BMI (kg/m2) 20.80±1.42 22.37±0.71 
1 st year    
HbA1c (%) 6.12±0.64* 7.96±1.80 
injected insulin (IU/kg of weight) 0.07±0.04* 0.54±0.25 
total insulin injected (IU) 5.43±1.29* 35.83±5.15 
C-peptide (pmol/L) 1.07±0.68 0.67±0.39 
IDAA1C 6.18±0.61* 10.23±1.90 
protein carbonyls (μmol/L) 80.73±10.28 87.49±19.25 
BMI (kg/m2) 21.40±1.33 24.41±1.08 
2 nd year    
HbA1c (%) 6.20±0.75* 8.50±1.96 
injected insulin (IU/kg of weight) 0.14±0.07* 0.61±0.29 
total insulin injected (IU) 7.67±1.94* 37.50±6.53 
C-peptide (pmol/L) 1.87±1.58 0.67±0.37 
IDAA1C 6.72±0.92* 10.96±2.28 
protein carbonyls (μmol/L) 88.48±19.67 91.87±12.56 
BMI (kg/m2) 21.57±1.25 24.06±1.12 
   
 
(*) Significant values (p<0.05) with respect to group S 
Results 
[Table 1] shows the determinations at the moment of onset and after 1 and 2 years of the circulating 
parameters (HbA1c, C-peptide and protein carbonyls), insulin requirements and body mass index (BMI) of 
patients from both groups that completed the study (n=19). Subjects that did not provide the necessary 
follow-up data were excluded from the study. HbA1c served as a marker for average glycaemia levels over 
long periods of time [13]. As it can be observed in [Table 1], group A presented at the time of onset 
significantly lower values of HbA1c than group S. Interestingly, after the first year, group A presented 
HbA1c values similar to those recommended by the American Diabetes Association (ADA) (6.5%) for the 
reduction of vascular complications [14]. At the end of the first and second year, group S presented 
acceptable HbA1c values, but were significantly higher than those found in group A. However, the change 
observed in HbA1c levels in both groups was similar (around 4%). 
 
Circulating C-peptide levels were determined in this study as an indicator of the existence of a 
residual pancreatic β-cell mass [15]. At the moment of onset, individuals from group A presented 3 times 
significantly higher values of circulating C-peptide than patients from group S ([Table 1]). Differences 
between both groups were not significant at the end of the first and second year, although the values of C-
peptide were always higher in group A compared to group S. The concentration of C-peptide determined 
at the end of the study in both groups was approximately twice the ones determined at the moment of 
onset. However, C-peptide levels are insufficient for detecting functionality in residual β-cells. The 
IDAA1C (insulin dose-adjusted HbA1c) index has been proposed to define the partial remission period 
(honeymoon phase) and values of IDAA1C≤9 strongly correlate with the existence of residual functional 
β-cells [16]. According to this, group A compared to group S displays IDAA1C values at the end of the 
first and second year that indicate the presence of functional endocrine pancreas ([Table 1]). 
 
In the clinical practice, the insulin administered to each patient is strongly related, among other 
factors, to glycaemic control and to the presence of a residual pancreatic endocrine function. According to 
data recorded in the clinical story of participants, we observed that individuals of group A required less 
insulin administration than subjects from group S, being significantly different at the end of the first and 
second year ([Table 1]). This is also reflected in the amount of total insulin units injected ([Table 1]). In 
addition, Pearson’s correlation analysis revealed that the average amount of insulin injected measured in 
units/kg of body weight moderately correlated with HbA1c levels at the end of the first year (r=0.545) and 
very positively at the end of the second year (r=0.768) in group A. However, there was less correlation 
between insulin requirements and C-peptide levels, being r=− 0.423 at the end of the first year and 
r=− 0.334 at the end of the second year. Therefore, the adequate glycaemic control as reflected by low 
HbA1c levels seems to be the main determinant for reduced insulin requirements. Regular exercise could 
be instrumental to achieve this goal. 
 
To verify this assumption, we applied the correlation analysis between exercise frequency and HbA1c 
levels, resulting in a moderate correlation at the moment of onset (r=− 0.528) and at the end of the first 
year (r=− 0.680), but good at the end of the second year (r=− 0.798). As expected, correlation between 
exercise frequency and insulin requirements evolved positively, being r=− 0.502 at the moment of onset, 
r=− 0.810 at the end of the first year and r=− 0.884 at the end of the second year. Nevertheless, correlation 
was moderate or low when comparing exercise frequency and C-peptide levels, being r=0.579 at the 
moment of onset, r=0.242 at the end of the first year and r=0.507 at the end of the second year. 
 
In an attempt to better understand the evolution of the disease in both groups of patients, we 
determined the levels of plasmatic protein carbonyls. This election was based on the observation that 
diabetes is a disease that presents oxidative stress events, with sustained hyperglycaemia being one of the 
main pro-oxidant disruptors [17]. This provokes the glycation of haemoglobin and possibly of other body 
proteins, developing over time oxidative adducts, including protein carbonyls. [Table 1] shows that there 
were no significant differences in the protein carbonyls of both groups, although group A tended to have 
slightly lower protein carbonyl values than group S. Finally, BMI did not present significant changes in 
both groups, although group A presented optimal values. 
 
Altogether, these results seem to indicate that practicing regular physical activity before and after the 
onset gives rise to a positive evolution of different parameters, in particular HbA1c levels. The question 
that arises is if there are other parameters that could be modulated by regular exercise. To this end, we 
focused on the immunological and inflammatory response, since they play an instrumental role in the 
progression and severity of disease [18]. In particular, we determined the levels of GAD antibodies, one 
of the most frequent autoantibodies in type 1 diabetes [19]. Interestingly, not all individuals presented 
positive antiGAD in circulation. In group A, 3 of the 8 individuals presented antiGAD values lower than 
1 U/mL, while in group S only one individual did not present antiGAD. For the rest of the individuals 
with positive antibody values, the antiGAD values varied greatly, ranging 2–34 U/mL in group A and 
1.2–30 U/mL in group S. Individually, we observed that antiGAD values remained unchanged throughout 
the whole period studied. Only one individual of group A presented a decrease in circulating antiGAD 
ranging from 3.9 U/mL at the moment of onset to 2 U/mL at the end of the second year. In group S, 2 
individuals presented a decrease, with 30 U/mL at the moment of onset and 6.4 U/mL at the end of the 
second year and from 4.7 to 1.9 U/mL for the second individual in the same period of time. Altogether, 
the obtained results do not allow us to establish a correlation between the frequency of exercise practice 
and the circulating levels of antiGAD. 
  
On the other hand, cytokines are involved in β-cell lesions in human and animal models of type 1 
diabetes [3]. In this context, the second question that arises is if physical activity could modulate certain 
circulating cytokine levels. We measured a number of cytokines that have shown to be instrumental in the 
development of type 1 diabetes playing pro- as well anti-inflammatory roles [3] [20]. When analyzed 
individually, we discovered that there was great variability among individuals, in other words, each 
individual presented their own cytokine profile. In addition, this profile changed in the same individual in 
response to a variety of external and internal stressors, being diabetes one of them. 
 
Nevertheless, the analysis of the error bar representations revealed interesting tendencies ([Fig. 2] [3]). 
At the moment of the onset of disease (Time 0), IL-4, IL-5, IL-9 and TNF-α presented a similar range of 
variability in individuals of group A and group S. At time 0, IL-1β, IL-17a, IL-22 and IFN-γ levels were 
more varied in individuals of group A than group S. The opposite was observed with IL-2, IL-10, IL-13 
and IL-12p70, which displayed wider variability in individuals of group S than group A. These patterns 
were maintained with more or less differences at the end of the first year for IL-1β, IL-9, IL-17a, IL-22 
and IFN-γ. However, at the end of the first year IL-2, IL-4, IL-5, IL-10, IL-13, IL-12p70 and TNF-α 
levels were more varied in individuals of group A than group S. Finally at the end of the second year, IL-
4, IL-13, IL-17a and IFN-γ presented the same pattern observed at the end of the first year. At the end of 
the second year, IL-9, IL-10 and TNF-α presented a higher range of variability in individuals of group S 
compared with group A. A similar range of variability at the end of the second year was observed for IL-2 
and IL-22, while IL-1β, IL-5 and IL-12p70 were not detected in either group. Basal IL-6 presented values 
under the detection limit of the technique in both groups during the study. 
 
 
 
Fig. 2 Circulating cytokine ranges for sedentary (S) and active (A) individuals. Results are represented by error bars indicating 95% 
confidence interval (CI) based on Student t-test for paired data. 
  
 
 
 
Fig. 3 Circulating cytokine ranges for sedentary (S) and active (A) individuals. Results are represented by error bars indicating 95% 
confidence interval (CI) based on Student t-test for paired data. 
The analysis of evolution from time 0 to the first year revealed almost significant differences for 
specific cytokines, such as IL-4 in group A (p<0.08) and IL-22 in group S (p<0.06). 
Discussion 
The presented results seem to indicate that individuals who practice regular physical activity before 
the onset of type 1 diabetes initiate with a better metabolic profile than sedentary individuals, presenting 
significantly lower levels of HbA1c and higher C-peptide levels. In addition, individuals of group A 
present less ketoacidosis cases (2 from n=8) than individuals of group S (7 from n=11). We can speculate 
that exercise before onset helps to a better prognosis of the disease. In this context, it has been described 
that ketoacidosis seems to be associated with a poor long-term metabolic regulation and residual β-cell 
mass [21]. In any case, additional experiments are necessary to verify this hypothesis. 
 
The results also emphasize that the Hospital’s educational program (which includes diet management 
and insulin injection monitoring) improved in a similar manner the management of the disease in both 
groups. In other words, during the 2 year period both groups presented a 4% decrease in HbA1c values 
and doubled circulating C-peptide levels. Since active individuals began the experimental period with a 
better circulating profile, this influenced at long term the functionality of residual β-cells as indicated by 
the values obtained for the IDAA1C index. These values indicate that active patients displayed an 
excellent metabolic control than sedentary, and that this event could be described as an extended 
honeymoon phase [16]. 
 
In this context, group A presented IDAAIC scores of 9 or less at the end of the first and second year. 
IDAA1C was used to define the honeymoon period, a moment that strongly correlates with the existence 
of residual functional β-cell mass [16]. Therefore we can hypothesize that the regular practice of physical 
activity before and after the onset of the disease allows individuals to enter in an optimal metabolic 
control period, similar in many aspects to the honeymoon phase mentioned before. This phase is 
characterised by presenting low levels of HbA1c, an indicator of correct glycaemia control, and therefore 
low requirements of exogenous insulin. The results of our study also emphasize that a sedentary lifestyle 
is not the best way to obtain certain metabolic advantages before the onset of the disease (compare groups 
A and S at time 0 in [Table 1]). In addition, diet and insulin injections are not sufficient to maintain an 
optimal metabolic control (i. e., individuals of group S) once the disease has been established, being the 
practice of regular physical activity the candidate factor to achieve both goals. Since this has been an 
observational study, we cannot provide data concerning frequency, intensity or type of activity that could 
be the most appropriate to prescribe to patients with type 1 diabetes. More studies are necessary to answer 
this particular point. 
 
Since active individuals possessed better metabolic circulating parameters than the sedentary 
counterparts at the moment of onset, we could speculate that individuals of group A might be diagnosed 
later than sedentary ones. However, the average age of admission at the Endocrinology Unit was very 
similar in both groups. Concerning this point, it is important to mention that the active individuals of this 
study were practicing sports in a semi-professional level and for this reason submitted more often to 
routine blood and medical analysis, which was how the disease was detected. In any case, the severity of 
the disease seems to be a particular feature of each individual, as reflected by the large variability in 
values for antiGAD and the cytokines analysed. In other words, for a similar severity of the disease 
included in a similar environmental and genetic background, individuals with an active lifestyle would 
develop the disease later than sedentary ones. Unfortunately this did not occur neither in our study nor in 
the majority of the studies conducted at present. For this reason, this remains as a speculative point that 
needs very precise experimental designs for its study. 
 
Several intervention and observational studies have analysed the impact of physical activity in 
diabetes control, but always once the pathology was established. In this respect, the changes in HbA1c, 
used as a marker of glycaemia management, observed in these studies were modest or not significant [9] 
[10]. In addition, we cannot compare these studies with ours due to several key differences. First, in this 
study active individuals were performing exercise before the onset of the disease. Second, the exercise 
frequency to be considered active for an individual in our protocol was at least of 5 days/week and 
1 h/day [11]. Regarding insulin requirements, both points seem to be instrumental in the subsequent 
management of the disease for individuals of group A (lower requirements) compared with those of group 
S, at least in a period of 2 years. 
A similar tendency in individuals of group A was observed for protein carbonyls, however the 
differences with group S were not significant. We can hypothesize that hyperglycaemia in type 1 diabetes 
favoured the development of oxidative stress [17]. In this context, an adequate glycaemic control could 
minimize oxidative damage. Furthermore, it is known that physical activity allows the activation of genes 
coding for antioxidant enzymes, leading to a better antioxidant defence [22]. Therefore, the modulation of 
oxidative stress in diabetic patients that perform regular exercise remains to be studied in more detail. 
 
On the other hand, exercise is capable of modulating cytokine production. However, these changes 
depend on intensity, type and duration of the exercise [23] [24]. In this context, several studies have 
shown that specific routines can increase circulating levels of anti-inflammatory cytokines that can 
control the muscle inflammatory damage inherent to exercise [25]. However, this does not seem to be as 
simple in a chronic disorder such as type 1 diabetes ([Fig. 2] [3]). Furthermore, the complexity to 
interpret the results increases if we take in account that the majority of the cytokines are produced in 
response to a variety of environmental stressors, explaining the inter-individual variability. Otherwise 
said, it seems that each patient has its own particular cytokine circulating profile. Moreover, the majority 
of the data concerning the role of cytokines in the development of type 1 diabetes are from animal studies, 
where islet tissue can be directly analysed [26]. Therefore, our results must be interpreted with extreme 
caution. 
 
Nevertheless and regarding this issue, some particular observations deserve further discussion. First of 
all, certain cytokines considered as pro-inflammatory in type 1 diabetes development were clearly 
detected in individuals of group A at the moment of onset, i. e., IL-1β, IL-17a, IFN-γ and TNF-α, and 
even at the end of the first year ([Fig. 2]). These results could suggest that exercise has some influence in 
controlling the inflammatory response. However, at the end of the first year, when in addition to exercise 
the individuals control diet and insulin administration, we have observed that anti-inflammatory cytokines 
such as IL-2, IL-4, IL-5, IL-10 and IL-13 are largely detectable in individuals of group A compared with 
group S ([Fig. 3]). The pattern observed was not maintained at the end of the second year ([Fig. 2] [3]). 
This could be tentatively interpreted that over time the anti-inflammatory effects attributed to exercise 
practice is not sufficient to stall the pro-inflammatory progression of the disease. 
 
IL-2 together with IL-21 is under the control of Idd3, a susceptible gene locus in diabetes 
development. Reduced levels of IL-2 in islets of NOD mice correlate with reduced function of Treg cells 
[27] [28]. In this context, IL-2 helps to keep the ratio in favour of CD4
+
-Treg cells in swollen islets [29] 
[30] and IL-4 avoids diabetes development by inducing Th2 cells in islet tissue [31]. In addition, IL-10 
also plays a protective role in diabetes development [32], although some findings are discrepant [33]. 
 
On the other hand, IL-22, which is included in IL-10 family, is an interesting cytokine that deserves 
some attention. IL-22 upregulates the expression of Reg genes in islets. These genes code for proteins 
such as Reg2 or Reg3β that are involved in β-cell regeneration [34] and are abundant in mouse pancreatic 
buds [35]. In addition, IL-22 receptor is expressed in pancreatic β and α-cells, but not in exocrine acinar 
or ductal epithelium [36]. Moreover, IL-6, which is acutely secreted after exercise performance in 
diabetes patients and has a shorter half-life than IL-22 [37] is capable of also activating Reg proteins [38]. 
We can hypothesize that IL-22 is secreted when the endocrine pancreatic mass is reduced to a critical 
level in order to restore β-cell mass by activating Reg proteins. However, we can speculate that this 
objective is not reached due to the high presence of pro-inflammatory cytokines in islet tissue. Although, 
some anti-inflammatory cytokines are present to counteract the effect of the pro-inflammatory factors, at 
least during the first year, they cannot establish an optimal situation to restore β-cell mass. In any case, 
new experiments need to be designed in order to confirm these hypotheses. 
 
Finally, one limitation of our study concerns the low number of individuals studied. Nevertheless, the 
majority of the published studies present similar figures [9] [10]. In conclusion, this report suggests that 
adequate circulating parameters could be reached when physical activity is performed before the onset of 
type 1 diabetes, resulting in an optimal insulin administration in subsequent periods. 
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